No biomarker
No biomarker
|
Leiomyosarcoma
Leiomyosarcoma
|
|
No biomarker
No biomarker
|
Leiomyosarcoma
Leiomyosarcoma
|
eribulin mesylate
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Leiomyosarcoma
Leiomyosarcoma
|
PTC596
Sensitive: B - Late Trials
|
Chr amplification(4)(q22.1)
Chr amplification(4)(q22.1)
|
Leiomyosarcoma
Leiomyosarcoma
|
eribulin mesylate
Resistant: C3 – Early Trials
|
Chr del(3)(q14.2)
Chr del(3)(q14.2)
|
Leiomyosarcoma
Leiomyosarcoma
|
eribulin mesylate
Resistant: C3 – Early Trials
|
Chr del(11)(q25)
Chr del(11)(q25)
|
Leiomyosarcoma
Leiomyosarcoma
|
eribulin mesylate
Resistant: C3 – Early Trials
|
Chr del(2)(q14.1)
Chr del(2)(q14.1)
|
Leiomyosarcoma
Leiomyosarcoma
|
eribulin mesylate
Resistant: C3 – Early Trials
|
Chr del(2)(p12)
Chr del(2)(p12)
|
Leiomyosarcoma
Leiomyosarcoma
|
eribulin mesylate
Sensitive: C3 – Early Trials
|
Chr del(1)(q44)
Chr del(1)(q44)
|
Leiomyosarcoma
Leiomyosarcoma
|
eribulin mesylate
Resistant: C3 – Early Trials
|
Chr amplification(8)(q13.2)
Chr amplification(8)(q13.2)
|
Leiomyosarcoma
Leiomyosarcoma
|
eribulin mesylate
Resistant: C3 – Early Trials
|
Chr amplification(8)(q22.2)
Chr amplification(8)(q22.2)
|
Leiomyosarcoma
Leiomyosarcoma
|
eribulin mesylate
Resistant: C3 – Early Trials
|
Chr amplification(13)(q13.3)
Chr amplification(13)(q13.3)
|
Leiomyosarcoma
Leiomyosarcoma
|
eribulin mesylate
Resistant: C3 – Early Trials
|
Chr amplification(20)(p12.2)
Chr amplification(20)(p12.2)
|
Leiomyosarcoma
Leiomyosarcoma
|
eribulin mesylate
Resistant: C3 – Early Trials
|
Chr amplification(4)(q26)
Chr amplification(4)(q26)
|
Leiomyosarcoma
Leiomyosarcoma
|
eribulin mesylate
Resistant: C3 – Early Trials
|
ATRX mutation
ATRX mutation
|
Leiomyosarcoma
Leiomyosarcoma
|
eribulin mesylate
Resistant: C3 – Early Trials
|
TP53 mutation
TP53 mutation
|
Leiomyosarcoma
Leiomyosarcoma
|
eribulin mesylate
Sensitive: C3 – Early Trials
|
ATRX mutation
ATRX mutation
|
Leiomyosarcoma
Leiomyosarcoma
|
dacarbazine
Resistant: C3 – Early Trials
|
TP53 mutation
TP53 mutation
|
Leiomyosarcoma
Leiomyosarcoma
|
dacarbazine
Resistant: C3 – Early Trials
|
AKT1 mutation + mTOR mutation
AKT1 mutation + mTOR mutation
|
Leiomyosarcoma
Leiomyosarcoma
|
TAK-228
Sensitive: C3 – Early Trials
|
|
Leiomyosarcoma
Leiomyosarcoma
|
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
|
MYH9-ALK + ALK-WDR43
MYH9-ALK + ALK-WDR43
|
Leiomyosarcoma
Leiomyosarcoma
|
crizotinib
Sensitive: C4 – Case Studies
|
PTEN mutation + TSC1 mutation
PTEN mutation + TSC1 mutation
|
Leiomyosarcoma
Leiomyosarcoma
|
TAK-228
Sensitive: C4 – Case Studies
|
NF1 mutation
NF1 mutation
|
Leiomyosarcoma
Leiomyosarcoma
|
IPN60090
Sensitive: C4 – Case Studies
|
PLK4 expression
PLK4 expression
|
Leiomyosarcoma
Leiomyosarcoma
|
CFI-400945
Sensitive: D – Preclinical
|
CSPG4 overexpression
CSPG4 overexpression
|
Leiomyosarcoma
Leiomyosarcoma
|
CSPG4.TNK
Sensitive: D – Preclinical
|
HAT1 overexpression
HAT1 overexpression
|
Leiomyosarcoma
Leiomyosarcoma
|
pazopanib
Resistant: D – Preclinical
|
MAN1A1-ROS1 rearrangement
MAN1A1-ROS1 rearrangement
|
Leiomyosarcoma
Leiomyosarcoma
|
crizotinib
Sensitive: D – Preclinical
|
